Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Merck
Chubb
Federal Trade Commission
Healthtrust
Mallinckrodt
Accenture
Farmers Insurance
Covington

Generated: October 23, 2018

DrugPatentWatch Database Preview

Daptomycin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for daptomycin and what is the scope of daptomycin patent protection?

Daptomycin is the generic ingredient in three branded drugs marketed by Cubist Pharms Llc, Crane Pharms Llc, Fresenius Kabi Usa, Hospira Inc, Mylan Labs Ltd, Teva Pharms Usa, Sagent Pharms, and Xellia Pharms Aps, and is included in eight NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for daptomycin. Six suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for daptomycin
Ingredient-typeLipopeptides
Drug ClassLipopeptide Antibacterial
Medical Subject Heading (MeSH) Categories for daptomycin
Synonyms for daptomycin
060D533
103060-53-3
2,2'-((3S,6S,9R,15S,18R,21S,24S)-30-((S)-2-((S)-4-amino-2-((S)-2-decanamido-3-(1H-indol-3-yl)propanamido)-4-oxobutanamido)-3-carboxypropanamido)-3-(2-(2-aminophenyl)-2-oxoethyl)-24-(3-amino
AB0012614
AB01274779_02
AB01274779-01
AC-1162
ACN-036875
AKOS005146218
AKOS024457871
AKOS025401343
AKOS026750170
AKOS032949840
AM000687
AM011338
AN-5525
Antibiotic A-21978 C0
AOB87734
AS-12931
BC677644
C12013
C72H101N17O26
CHEBI:600103
CHEMBL1649722
CHEMBL387675
CHEMBL404822
Cidecin
CS-1857
Cubicin
Cubicin (TN)
Cubicin Rf
D01080
D05HPI
D4229
Dapcin
Daptomicina
Daptomicina [Spanish]
Daptomycin (JAN/USAN/INN)
Daptomycin [USAN:INN:BAN]
Daptomycin for injection
Daptomycin Ready Made Solution
Daptomycin, cyclic lipopeptide antibiotic
Daptomycine
Daptomycine [French]
Daptomycinum
Daptomycinum [Latin]
DB00080
Deptomycin
DOAKLVKFURWEDJ-RWDRXURGSA-N
HY-B0108
LS-171846
LY 146032
LY-146032
LY146032
MFCD08282794
MK-3009
MolPort-003-846-138
MolPort-023-276-990
MolPort-046-033-485
N-(1-Oxodecyl)-L-tryptophyl-D-asparaginyl-L-?-aspartyl-L-threonylglycyl-L-ornithinyl-L-?-aspartyl-D-alanyl-L-?-aspartylglycyl-D-seryl-(3R)-3-methyl-L-?-glutamyl-?,2-diamino-?-oxo-benzene butanoic acid (13-4) lactone
N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone
N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone
N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone
N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone
N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone
N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,
NCGC00346517-01
NWQ5N31VKK
propyl)-6-(1-carboxypropan-2-yl)-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane-15,21-diyl)diacetic acid
Q-200927
S-7668
s1373
SCHEMBL13491700
SCHEMBL1650768
SCHEMBL28102
SCHEMBL8221756
SCHEMBL8221760
UNII-NWQ5N31VKK
Tentative approvals for DAPTOMYCIN
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up350MG/VIALPOWDER;INTRAVENOUS

US Patents and Regulatory Information for daptomycin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Crane Pharms Llc DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 206005-001 Jun 15, 2016 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms Usa DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 091039-001 Mar 25, 2016 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius Kabi Usa DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 206077-001 Apr 11, 2018 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sagent Pharms DAPTOMYCIN daptomycin POWDER;IV (INFUSION) 208385-001 Sep 12, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for daptomycin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 ➤ Sign Up ➤ Sign Up
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 ➤ Sign Up ➤ Sign Up
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 ➤ Sign Up ➤ Sign Up
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for daptomycin

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB06/024 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
/2006 Austria ➤ Sign Up PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
22/2006 Austria ➤ Sign Up PRODUCT NAME: DAPTOMYCIN
C0022 France ➤ Sign Up PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
2006 00018 Denmark ➤ Sign Up PRODUCT NAME: DAPTOMYCIN
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Merck
Chubb
Federal Trade Commission
Healthtrust
Mallinckrodt
Accenture
Farmers Insurance
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.